FilingSEC EDGAR6-K
Veraxa Biotech Presents In Vivo Proof-of-Concept Data for BiTAC-ADC Platform
· SEC accepted
StagePreclinical
Filing content
Veraxa Biotech presented in vivo data demonstrating tumor reduction and safety for its BiTAC-ADC technology platform.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…